Vivos Therapeutics, Inc. — Form 8-K
Filed October 21, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 72/100
What the filing says
Vivos Therapeutics received Nasdaq confirmation on October 20, 2026, that it meets the minimum $2.5M stockholders' equity listing requirement. This compliance follows closure of an acquisition of 11% equity in SOD Sciences and 50% co-ownership of SOD's pseudohypoxia diagnostic test, funded by issuance of 12,000 shares of Series C Convertible Preferred Stock with $12M stated value. The preferred stock, convertible at $0.15/share into up to 80M common shares (subject to 19.99% cap and 4.99% ownership limits pending shareholder approval), is expected to increase stockholders' equity by >$10M.
Why this rating
Company was at delisting risk; $12M transaction (~52% of market cap) and Nasdaq clearance restore trading viability and provide equity cushion. Critical for survival but not transformational growth.
Price action (we called it positive)
before filing · preread $0.13 | at our read pending | +10 min pending | +30 min pending | +1 hr pending | +4 hrs pending |
Quotes via Yahoo Finance at capture time; for filings arriving outside market hours the clock starts at the next open. Not investment advice. How accurate are our calls? →
See more from October 21, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.